Skip to content

Optical Coherence Tomography and Optic Neuritis Not Related to Multiple Sclerosis

Evaluation and Follow-up of Optic Neuritis Not Related to Multiple Sclerosis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03963310
Acronym
OCTON2
Enrollment
38
Registered
2019-05-24
Start date
2020-09-14
Completion date
2024-05-23
Last updated
2025-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Optic Neuritis

Brief summary

The visual prognosis of optic neuritis not related to multiple sclerosis is unknown, both in terms of functional recovery and evolution. This prospective cohort study aim to assess the ophthalmological evolution of patients presenting an episode of optic neuritis (NO) not related to a multiple sclerosis or to a clinically isolated syndrome.

Interventions

None listed

Sponsors

Fondation Ophtalmologique Adolphe de Rothschild
Lead SponsorNETWORK

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* First onset of an optic neuritis lasting for less than 1 month * With a brain MRI that does not meet the MS criteria

Exclusion criteria

* Contra-indication to MRI * Pregnant or lactating woman * History of known ipsilateral optic neuritis * Ophthalmologic comorbidity in the ipsilateral eye that may interfere with the interpretation of the examinations

Design outcomes

Primary

MeasureTime frameDescription
Visual acuity (ETDRS scale)1 yearEvolution over 1 year of the ophthalmological parameters of patients treated for an episode of optic neuritis not related to multiple sclerosis or a clinically isolated syndrome
Thickness of the layers of the retina with Optical Coherent Tomography(OCT),1 year
Standard Humphrey Visual Field Test1 year

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026